CoreRx Acquires Nucleo Life Sciences
May 24, 2021
CoreRx, Inc. has acquired Nucleo Life Sciences, a boutique CDMO based in San Rafael, California, expanding CoreRx’s US West Coast development presence and formulation capabilities. The deal, supported by CoreRx’s majority owner NovaQuest Private Equity and other shareholders, will integrate Nucleo’s Fast-to-Clinic formulation expertise (including spray-dried dispersions and NucleLoad) into CoreRx’s development and manufacturing platform.
- Buyers
- CoreRx, Inc.
- Targets
- Nucleo Life Sciences
- Platforms
- CoreRx, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Red Nucleus Acquires COEUS
February 4, 2025
Healthcare Services
Red Nucleus, a global strategic partner to life sciences companies, has acquired COEUS, a market access consulting and communications firm. The deal augments Red Nucleus' market access capabilities—particularly payor outreach, HEOR, patient access, and commercialization support—strengthening services for pharmaceutical and biotech clients.
-
Bend Bioscience Unites CoreRx and Societal CDMO Under Single Bend Bioscience Brand
September 4, 2024
Pharmaceuticals
Bend Bioscience has unified CoreRx and Societal CDMO under the Bend Bioscience brand to form an integrated contract development and manufacturing organization (CDMO). The consolidation combines CoreRx’s formulation development expertise, Societal CDMO’s scalable cGMP manufacturing and packaging capabilities, and Bend Bioscience’s research and technology to offer end-to-end development-to-commercialization services across facilities in Bend, Oregon; Clearwater, Florida; and Gainesville, Georgia.
-
CoreRx, Inc. Acquires Societal CDMO, Inc.
April 8, 2024
Pharmaceuticals
CoreRx, Inc. completed its acquisition of Societal CDMO, Inc. through a tender offer and subsequent short-form merger, acquiring approximately 92.8% of outstanding shares at $1.10 per share. Societal CDMO is now a wholly owned subsidiary of CoreRx and its common stock will be delisted from the Nasdaq Capital Market.
-
Red Nucleus Acquires Jupiter Life Science Consulting
September 12, 2022
Consulting
Red Nucleus, a Riverside-backed life sciences services platform, has acquired Jupiter Life Science Consulting, a boutique provider of market access and commercialization strategies for pharma, biotech, and medical device clients. The add-on expands Red Nucleus's commercial and market-access capabilities, bringing Jupiter's expertise in payer research, pricing and access strategy, and commercialization planning into the combined platform.
-
Fortis Life Sciences Acquires Abcore
March 2, 2022
Biotechnology
Fortis Life Sciences has acquired Abcore, an antibody discovery platform specializing in nanobody technologies, to expand Fortis’ antibody product and service capabilities. The acquisition brings Abcore’s end-to-end discovery and custom antibody production capabilities into the Fortis platform to accelerate commercial and operational scale-up for biopharma and diagnostic customers.
-
NovaQuest Private Equity Acquires CoreRx, Inc.
January 19, 2021
Pharmaceuticals
NovaQuest Private Equity acquired CoreRx, Inc., a Clearwater, Florida–based contract development and manufacturing organization (CDMO). Affiliates of Signet Healthcare Partners will retain a minority stake; Goldman Sachs Specialty Lending Group provided debt financing. NovaQuest said the investment will support continued growth and capability expansion of CoreRx's clinical and commercial CDMO services.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.